Mycophenolate mofetil (MMF)

Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

Immunosuppressants Mycophenolate mofetil (MMF) 1-1.5g PO Q12H Administer Anytime During HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
434 > 90 MMF - PO:18h, IV:17h; mycophenolic acid - PO 8-16h, inactive metabolite MPAG (mycophenolic acyl glucuronide) 13-17h N/A 82-97 3.6 N/A No (low flux)


  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL:
  • Mycophenolate. In:Lexi-Drugs Online. Hudson (OH): Lexi-Comp, Inc,; [updated 04/23/12; accessed 04/23/12].
  • MacPhee I, Spreafico S, Bewick M et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney International 2000; 57, 1164-1168.
  • Schleibner S, Schneeberger H, Krauss M, Land W. Mycophenolate mofetil in patients with acute renal failure : evidence of metabolite (MPAG) accumulation and removal by dialysis. Annals of Surgery 1996; 9(Suppl 1), S308-S310.